145 related articles for article (PubMed ID: 25710919)
21. [Towards a holistic vision of cancer].
Solary É; Laplane L
Med Sci (Paris); 2016 Apr; 32(4):315-6. PubMed ID: 27137681
[No Abstract] [Full Text] [Related]
22. Antibody-targeted immunotherapy for treatment of malignancy.
White CA; Weaver RL; Grillo-López AJ
Annu Rev Med; 2001; 52():125-45. PubMed ID: 11160771
[TBL] [Abstract][Full Text] [Related]
23. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
[TBL] [Abstract][Full Text] [Related]
24. [New era of tumor immunotherapy].
Yoshitake Y; Nakatsura T; Nishimura Y
Nihon Rinsho; 2005 Apr; 63 Suppl 4():46-55. PubMed ID: 15861634
[No Abstract] [Full Text] [Related]
25. Dual antibody therapy to harness the innate anti-tumor immune response to enhance antibody targeting of tumors.
Chester C; Marabelle A; Houot R; Kohrt HE
Curr Opin Immunol; 2015 Apr; 33():1-8. PubMed ID: 25576932
[TBL] [Abstract][Full Text] [Related]
26. Advances and outlooks for immunotherapy of cancer.
Steplewski Z
Hybridoma; 1993 Oct; 12(5):493-500. PubMed ID: 8300120
[No Abstract] [Full Text] [Related]
27. Programmed death-1 inhibition in renal cell carcinoma: clinical insights and future directions.
Pal SK; Hu A; Chang M; Figlin RA
Clin Adv Hematol Oncol; 2014 Feb; 12(2):90-9. PubMed ID: 24892254
[TBL] [Abstract][Full Text] [Related]
28. PD-L1 Testing in Cancer: Challenges in Companion Diagnostic Development.
Hansen AR; Siu LL
JAMA Oncol; 2016 Jan; 2(1):15-6. PubMed ID: 26562503
[No Abstract] [Full Text] [Related]
29. Optimism after much pessimism: what next?
Milstein C; Waldmann H
Curr Opin Immunol; 1999 Oct; 11(5):589-91. PubMed ID: 10508713
[No Abstract] [Full Text] [Related]
30. New response criteria proposed for immunotherapies.
Tuma RS
J Natl Cancer Inst; 2008 Sep; 100(18):1280-1. PubMed ID: 18780859
[No Abstract] [Full Text] [Related]
31. MUC1 immunotherapy.
Beatson RE; Taylor-Papadimitriou J; Burchell JM
Immunotherapy; 2010 May; 2(3):305-27. PubMed ID: 20635898
[TBL] [Abstract][Full Text] [Related]
32. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
Khawli LA; Hu P; Epstein AL
Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
[TBL] [Abstract][Full Text] [Related]
33. Serotherapy of cancer.
Harris DT; Mastrangelo MJ
Semin Oncol; 1989 Jun; 16(3):180-98. PubMed ID: 2658082
[No Abstract] [Full Text] [Related]
34. Tetraspanin CD151 as a target for antibody-based cancer immunotherapy.
Haeuw JF; Goetsch L; Bailly C; Corvaia N
Biochem Soc Trans; 2011 Apr; 39(2):553-8. PubMed ID: 21428938
[TBL] [Abstract][Full Text] [Related]
35. PD-L1 expression by circulating breast cancer cells.
David R
Lancet Oncol; 2015 Jul; 16(7):e321. PubMed ID: 26095782
[No Abstract] [Full Text] [Related]
36. Advances in Cancer Therapy: Immunotherapies.
Marmé D
Oncol Res Treat; 2016; 39(6):324-5. PubMed ID: 27260772
[No Abstract] [Full Text] [Related]
37. Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities.
Merelli B; Massi D; Cattaneo L; Mandalà M
Crit Rev Oncol Hematol; 2014 Jan; 89(1):140-65. PubMed ID: 24029602
[TBL] [Abstract][Full Text] [Related]
38. [Immunotherapy for cancer--modern immunologic strategies in oncology].
Halama N; Zoernig I; Jäger D
Dtsch Med Wochenschr; 2008 Oct; 133(41):2105-8. PubMed ID: 18985564
[TBL] [Abstract][Full Text] [Related]
39. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
Ott PA; Hodi FS; Robert C
Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic antibodies: Discovery, design and deployment.
Ramsland PA; Hutchinson AT; Carter PJ
Mol Immunol; 2015 Oct; 67(2 Pt A):1-3. PubMed ID: 25990602
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
